Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Heavy metal containing DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514494000 Zinc 32
514502000 Iron 16
514495000 Gold or silver 14
514499000 Copper 5
20110112188Treatment of Inflammatory Conditions - The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.05-12-2011
20130150440USE OF BIS [THIOHYDRAZIDE AMIDE] COMPOUNDS SUCH AS ELESCLOMOL FOR TREATING CANCERS - Improved cancer treatments with bis[thiohydrazide amide] compounds such as elesclomol, in particular for identifying patient populations that would benefit from such treatments.06-13-2013
20110294877TRANSITION METAL COMPLEXES OF BIS[THIOHYDRAZIDE AMIDE] COMPOUNDS - The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I), or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. In one embodiment, the compound is represented by Structural Formula (II), or a prodrug, isomer, ester, salt, hydrate, solvate or polymorph thereof. The present invention also provides a pharmaceutical composition comprising the compound of the invention and method of use thereof.12-01-2011
20090258943Hybrid strategies for reducing leaching of metal biocides from biodegradable substrates - Hybrid strategies generally involve treating biodegradable substrates with preservative compositions having at least two phases in which the metal biocide is distributed among at least the two phases and via equilibrium reactions moves between the two phases. Both phases are caused to contact the substrate in a manner so that the phases are in contact with each other during at least a portion of the treatment. In illustrative embodiments, the first phase is a liquid phase comprising complexed metal biocide dissolved in a liquid carrier, while the second phase comprises particles comprising the metal biocide, often precipitated and/or colloidal particles. The strategies and related compositions, processes, and treatments are hybrid in the sense that the strategies include both heterogeneous (insoluble) and homogeneous metal biocide constituents. Unlike heterogeneous strategies, hybrid strategies are less sensitive to particle size constraints and may use biocide particles with a wider range of particle sizes. Unlike homogeneous strategies, hybrid strategies are less sensitive to pH and may use a wider range of complexing agents, including mildly alkaline amines such as triethanolamine.10-15-2009
20100016426Post-impregnation treatments to improve distribution of metal biocides in an impregnated substrate - The present invention relates to post-treatment compositions and methods useful for modifying the distribution of metal biocide(s) in biodegradable substrates such as wood, other cellulosic products, starch-based products, and the like that are vulnerable to decay due to insects, fungi, microbes, and the like. The compositions include complexing agents of moderate strength that are able to facilitate mobilization and redistribution of metal biocide(s) in substrates without undue leaching. The compositions can be used, for example, to redistribute the metal biocide(s) into depleted regions of a substrate by redistribution of metal biocide from other regions of the substrate. Post-treatment compositions that include additional metal biocide can also replenish these regions with the freshly supplied, additional biocide. Thus, the depleted regions can be restored by redistribution and/or replenishment mechanisms. Service life of substrates in the field benefits by these post-treatments as a consequence.01-21-2010
514504000 Arsenic 4
20130041027Organo-Arsenoxide Compounds and Use Thereof - The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.02-14-2013
20100041749Organo-Arsenoxide Compounds and Use Thereof - The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.02-18-2010
20090082439ORGANIC LIGHT-EMITTING DEVICE AND DISPLAY APPARATUS - An organic light-emitting device adapted for coating and having good emission efficiency and luminance. The organic light-emitting device employs an anode, a cathode, and a layer including an organic compound sandwiched between the anode and cathode. The layer containing the organic compound includes a bisfluorene compound represented by General Formula [1] below.03-26-2009
20100331403COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER - The present invention provides methods of synthesizing organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.12-30-2010
514503000 Antimony or bismuth 3
20090005443Treatment of Depression - There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof, for the treatment or alleviation of depression. There is also described a method of treating a patient suffering from depression.01-01-2009
20110086911NOVEL BISMUTH(III) NSAID COMPOUNDS AND METHODS FOR THEIR USE - The present invention relates to the field of non-specific anti inflammatory drugs (NSAIDs). In particular, the invention relates to bismuth(III) tris-carboxylate complexes having the formula [Bi(III)L04-14-2011
20110092589Treatment of Inflammatory Conditions and Diseases with Metal-Thiols - The present invention provides a method for the treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a metal and a thiol. In particular, embodiments of the present invention are directed towards methods of treating inflammatory conditions that are associated with elevated levels of free TNFα. In one embodiment, the present invention can be used to treat and/or ameliorate the effects of a wide variety of diseases or disorders related to an inflammatory condition including one or more of the following inflammation related diseases/disorders: arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome, chronic obstructive respiratory diseases (COPD), fibromyalgia and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.04-21-2011
514493000 Tin 2
20110054019Cancer Starvation Therapy - The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.03-03-2011
20120016022AGROCHEMICAL COMPOSITION FOR PEST CONTROL AND PEST CONTROL METHOD - The invention has as its object the provision of an agrochemical composition for pest control, by which an excellent control effect is achieved on pests, hyposensitive mites having reduced sensitivity to chemicals and eggs of the mites, and other pests of all stages of growth than the mites even when the composition is applied in a small amount, and a pest control method.01-19-2012
514501000 Nickel or cobalt 2
20100069487METHOD FOR THE TREATMENT OF PSORIASIS - A method for the therapeutic treatment of psoriasis by the administration of an anti-psoriasis effective amount of Doxivir (CTC-96) is discloses.03-18-2010
20100160429Anti-bacterial plant compositions - The invention provides a pharmaceutical composition which comprises a pharmaceutical carrier and at least one compound selected from the group consisting of cobaltocene-octamethyl, stigmastan-3,5-diene, galoxolide, benzyl salicylate, eucalyptol, and α-pinene. Also provided is a method of preparing a composition having antimicrobial activity comprising extracting a plant material in an organic solvent, contacting the extracted material to a chromatographic column, and eluting from the chromatographic column with a mobile polar phase to obtain a composition. The plant material is from 06-24-2010
514496000 Mercury 1
20110230554Method of Treating Viral Infections by Administration of Ethyl Mercury or Thiol Derivative Thereof - Disclosed herein are methods of treating viral infections by administration of ethyl mercury or thiol derivative thereof in an amount effective to treat the viral infection.09-22-2011
Entries
DocumentTitleDate
20120184611SELENOQUINONE-DERIVED ACTIVE ORGANOMETALLIC COMPLEXES, METHODS FOR SYNTHESIZING SAME, AND USES THEREOF - The present invention relates to the synthesis of novel biologically active selenoquinone-derived organometallic complexes, and to the uses thereof in the context of preventing or treating cancer.07-19-2012
20130158109RHENIUM COMPLEXES AND THEIR PHARMACEUTICAL USE - The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R′ is a phenyl group or a group of general Formula —(CH06-20-2013
20100105770Therapeutic delivery of carbon monoxide - Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ Mn complexes having CO ligands, and additional halogen, monodentate and/or bidentate ligands, wherein the additional ligands do not occupy trans positions relative to each other.04-29-2010
20100069486ANTI-TUMOR COMPOSITION - The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.03-18-2010
20100076076NOVEL PALLADIUM COMPLEXES INHIBIT N-MYRISTOYLTRANSFERASE ACTIVITYIN VITRO AND CANCER GROWTH IN VIVO - Melanoma is a solid tumor that is notoriously resistant to chemotherapy, and its incidence is rapidly increasing. Recently, several signaling pathways have been demonstrated to contribute to melanoma tumorigenesis, including constitutive activation of MAP kinase, Akt and stat-3. The activation of multiple pathways may account in part for the difficulty in treatment of melanoma. In a recent screen of compounds, we found that an organopalladium complex showed significant antiproliferative activity against melanoma cells. This complex, tris(dibenzylideneacetone)dipalladium (Tris DBA), has activity against B16 murine and A375 human melanoma in vivo. Tris DBA inhibits several signaling pathways including activation of MAP kinase, Akt, stat-3 and S6 kinase activation. Tris(dibenzylideneacetone)dipalladium is thus a novel compound that is a member of a class of noble metal complexes with potential antitumor activity. Further preclinical evaluation of TrisDBA and related complexes is warranted.03-25-2010
20100087521BIOLOGICALLY ACTIVE COMPLEX - The invention relates to an aqueous solution containing at least one species selected from the group consisting of a 1:1 molar complex of TeO04-08-2010
20090275655Pharmaceutical Gallium Compositions and Methods - The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, Paget's disease, and infections.11-05-2009
20110144202CONCENTRATED OXALIPLATIN SOLUTION AND ITS METHOD OF PREPARATION - The present invention relates to a pharmaceutically stable and highly concentrated aqueous oxaliplatin solution. The present invention also concerns a method for preparing said solution.06-16-2011
20090082437Use of Oxaliplatin for Enhancing Radiosensitivity in Radiotherapy of Cervical Cancer - The present invention relates to a method for enhancing radiosensitivity in radiotherapy of cervical cancer by administering to cervical cancer cells an effective amount of oxaliplatin. Radiation combined with pretreatment of oxaliplatin according to the present invention helps to enhance the cytotoxicity of radiation and result in augmenting radiation-induced mitotic catastrophe. The analysis on molecular mechanism revealed that oxaliplatin augmented the radiation-induced DNA double-strand break indicated by reducing gamma-H2AX expression, abrogated radiation-induced ATM phosphorylation and reduced the Chk2 phosphorylation. Oxaliplatin can be used as a promising radiosensitizer for treatment of cervical cancer in radiotherapy.03-26-2009
20110263702Methods and Compositions for Improved Chromium Complexes - Complex metal-containing matrices, and especially chromium-containing matrices are produced from a water soluble preparation that is derived from an item suitable for animal (and most typically human) consumption. In particularly contemplated aspects, the water soluble preparation is an extract or filtrate of disintegrated brewer's yeast, and the so prepared complex mixture is combined with a chromium-310-27-2011
20100267825TREATMENT OF SKIN DAMAGE - Methods and apparatus are disclosed for diagnosing and treating oxidative skin damage in a subject. The therapeutic method can comprise: (i) diagnosing a level of oxidative skin damage in a sample comprising stratum corneum of the subject; and (ii) recommending a therapeutic regime for treatment of oxidative skin damage in the subject, wherein said recommendation comprises a recommendation to administer a pharmaceutical formulation comprising an amount of one or more specific synthetic SOD/catalase mimetics sufficient to treat the level of oxidative skin damage of the subject as diagnosed. The diagnostic method can further include obtaining a sample from the stratum corneum of a subject; measuring the level of at least one oxidized substance in the sample; and comparing a detected level of the oxidized substance with a standard, whereby an elevated level of the oxidized substance is indicative of skin damage.10-21-2010
20110207814Combination Therapy for Breast Cancer Treatment - The present invention provides a novel treatment which features immune therapy in the context of the functions of MSCs as a novel approach to breast cancer treatment. By identifying and elucidating the role of MSCs in the behavior of breast cancer cells at metastatic sites and also at the primary region, this invention provides novel approaches for therapeutic intervention. More particularly, in the presence of MSCs a CXCR4 antagonist transitioned BCCs into cycling cells and conferred susceptibility to a chemotherapeutic agent. The proliferation of BCCs depended on the release of IL-1α and IL-1β from MSCs, but only if the CXCR4 antagonist uncoupled BCCs from MSCs.08-25-2011
20090275654Pharmaceutical Gallium Compositions and Methods - The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, and Paget's disease.11-05-2009
20090182043Pharmaceutical Preparation of Aqueous Solution Containing Platinum Complex - To provide an aqueous pharmaceutical preparation of a platinum complex which has no fear of contaminating a compounder with a drug with cytotoxicity, can be prepared by a simple operation, has a compact size, and is suppressed from deteriorating of drug during a long-term storage, an aqueous pharmaceutical preparation of a solution of a platinum complex in a stable state, in which an aqueous solution containing a platinum complex is contained in an oxygen-permeable container, and the oxygen-permeable container is contained in an oxygen-barrier container, the preparation being characterized in that the gap between the oxygen-barrier container and the oxygen-permeable container is filled with gas containing oxygen.07-16-2009
20090143464Method for preventing and/or treating peripheral Neuropathies induced by the administration of an anticancer agent - A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance the supportive effect of physiological NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy.06-04-2009
200802343693,4,5,4' - TETRAMETHOXYL- ALPHA,BETA-DIPHENYLETHANE -3' -0- SODIUMSULPHATE AND ITS USE - This invention relates to a compound of formula (I), 3,4,5,4′-tetramethoxyl-α,β-diphenylethane-3′-O-sodium sulphate, and its use in the preparation of antineoplastic pharmaceutical.09-25-2008
20080319061Process for the Preparation of an Oxaliplatin Preparation - The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.12-25-2008
20090093540ANTI-TUMOR COMPOSITION - The present invention provides compositions having, as active ingredients, a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.04-09-2009
20100184854PLATINUM (IV) COMPLEXES AND METHODS OF USE THEREOF - Provided are nitroplatinum(IV) complexes which may be useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages.07-22-2010
20090076139DEUTERIUM-ENRICHED OXALPLATIN - The present application describes deuterium-enriched oxaliplatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20130217765MULTIFUNCTIONAL NANOCONJUGATES AND USES THEREOF - The present invention provides multifunctional nanoconjugates and methods of using them to destroy biological and chemical agents. The nanoconjugates include a dye-coated metal oxide nanoparticles conjugated to a substance capable of binding specifically or non-specifically to an agent. Specifically, the nanoconjugates can be photoactivated by visible light to degrade and destroy biological agents, such as but not limited to bacteria and viruses.08-22-2013
20090312417PLATINUM(II) COMPLEXES, PREPARATION AND USE - The invention relates to a method for the preparation of platinum (II) complexes, in particular dicarboxylatoplatinum (II) complexes containing a neutral bidentate ligand, such as oxaliplatin. The method includes the step of reacting a bis-dicarboxylatoplatinate (II) species with a suitable neutral bidentate ligand to form a neutral dicarboxylatoplatinum (II) complex and, if necessary, recrystallising the product to form a pure dicarboxylatoplatinum (II) complex containing a neutral bidentate ligand. The invention also relates to a method for producing a bis-dicarboxylatoplatinate (II) species, and to new platinum (II) complexes that can be made by the method of the invention.12-17-2009
20100056625NON-TOXIC ANTI-CANCER DRUG COMBINING ASCORBATE, MAGNESIUM AND A NAPHTHOQUINONE - Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of “MgVC03-04-2010
20100063145ACID CONTAINING OXALIPLATIN FORMULATIONS - There is provided a pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation having (i) oxaliplatin; (ii) water; and (iii) an acid wherein the acid is stabilising and is not malonic acid, lactic acid or oxalic acid. Methods of preparing the formulation are also disclosed. There is further provided the use of the formulation in the preparation of a medicament for the treatment of cancer and a method for treating cancer which comprises administering a therapeutic amount of a pharmaceutical formulation.03-11-2010
20100173988OXALIPLATIN ACTIVE SUBSTANCE WITH A VERY LOW CONTENT OF OXALIC ACID - The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.07-08-2010
20100267824STABLE OXALIPLATIN COMPOSITION FOR PARENTERAL ADMINISTRATION - The present invention relates to a stable parenteral composition of oxaliplatin having pH range in between 3 to 4.5, which comprises of a solution of oxaliplatin in water wherein the said pH is attained by sparging of carbon dioxide in the composition. Further, a method for the preparation of oxaliplatin composition of the present invention is also disclosed.10-21-2010
20090209641PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION BY INJECTION - A pharmaceutical composition for administration by injection, comprising a mixture of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH08-20-2009
20100035982OXALIPLATIN FORMULATIONS - The present invention provides a pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation having (i) oxaliplatin, (ii) water; and (iii) an additive selected from the group of tartaric acid, a salt of tartaric acid, a pharmaceutically acceptable derivative of tartaric acid and mixtures thereof.02-11-2010
20100093849OXALIPLATIN PHARMACEUTICAL COMPOSITION WITH ALCOHOLIC SUGAR-BASED BUFFER - A pharmaceutical composition, intended particularly for potential administration and for treatment of tumor diseases sensitive to oxaliplatinum, comprises oxaliplatinum as the active compound, a pharmaceutically acceptable aqueous solvent and a stabilizing agent in stabilizingly effective amount. The stabilizing agent includes at least one compound selected from the group consisting of acids derived from neutral alcoholic sugars, lactones of these acids and salts of these acids. In a method of producing such a pharmaceutical composition, oxaliplatinum is dissolved in an aqueous solvent, whereupon to the obtained oxaliplatinum solution is added at least one acid derived from a neutral alcoholic sugar and/or at least one lactone of these acids and/or at least one salt of these acids, and optionally the pH value of the solution is adjusted by addition of an alkali metal hydroxide and/or an alkali earth metal hydroxide to pH 3.5-6.5, whereupon the obtained solution is sterilized and filled into individual package units and optionally inertized with nitrogen or argon.04-15-2010
20090082438Coordination Compound Composed of Diaminocyclohexane Platinum (II) and Block Copolymer and Anti-Cancer Agent Comprising the Same - The invention discloses a coordination compound comprising (1,2-diaminocyclohexane)platinum (II) moiety and poly(ethylene glycol)-block-poly(glutamic acid) copolymer moiety; and its use as an anti-cancer agent. The characteristic feature lies in the use of a copolymer whose poly(glutamic acid) segment has a chain length consisting of, on an average, less than 35 repeating units.03-26-2009
20100048697WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS - Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.02-25-2010
20100010083PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A′ independently of one another are an NH01-14-2010
20100292322Bis-Platinum Complexes With Antitumor Activity - A compound of general formula (I): in which: R is selected from the group consisting of (C11-18-2010
20100249226TUMOR SELECTIVE AND BIODEGRADABLE CYCLOTRIPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTICANCER AGENT, AND PREPARATION METHOD THEREOF - Disclosed are a novel cyclotriphosphazene-platinum(II) complex conjugate anticancer agent, showing high selectivity to tumor tissues due to the enhanced permeability and retention effect in tumor tissues and a preparation method thereof.09-30-2010
20120289592ERCC1 GENE EXPRESSION LEVEL IS ASSOCIATED WITH CLINICAL OUTCOMES IN ESOPHAGEAL CANCER PATIENTS - The disclosure provides compositions and methods for identifying a cancer patient, such as an esophageal cancer patient, suitable for a therapy that includes administration of a platinum drug and radiation pre-operatively, based on the expression level of an ERCC1 gene. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating the patients.11-15-2012
20130018096PLATINUM COMPLEX WITH ANTITUMOR ACTIVITYAANM De Munari; SergioAACI MilanAACO ITAAGP De Munari; Sergio Milan ITAANM Di Giovine; StefanoAACI MilanAACO ITAAGP Di Giovine; Stefano Milan ITAANM Grugni; MarioAACI MilanAACO ITAAGP Grugni; Mario Milan ITAANM Nicoli; PaolaAACI MilanAACO ITAAGP Nicoli; Paola Milan ITAANM Paganelli; AlessandroAACI MilanAACO ITAAGP Paganelli; Alessandro Milan ITAANM Pardi; GianlucaAACI San Giuliano Terme (Pisa)AACO ITAAGP Pardi; Gianluca San Giuliano Terme (Pisa) ITAANM Pezzoni; GabriellaAACI MilanAACO ITAAGP Pezzoni; Gabriella Milan IT - The present invention relates to the antitumor compound of formula (I) a process for its preparation and pharmaceutical compositions containing it.01-17-2013
20130172408Medicaments Based on Dinuclear Arene Ruthenium Complexes Comprising Bridging Thiolato, Selenolato or Alkoxo Ligands - The present invention provides new complexes and medicaments based on dinuclear ruthenium complexes comprising bridging thiolato or selenolato ligands. The complexes comprise a Ru07-04-2013
20100286263Gallium complexes with polyalcohols and methods of use - Provided are complexes of gallium and polyalcohols. Also provided are pharmaceutical compositions comprising such complexes and methods of their use. Methods of preparing the complexes are also provided.11-11-2010
20110257261PLATINUM (IV) COMPLEXES FOR USE IN DUAL MODE PHARMACEUTICAL THERAPY - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.10-20-2011

Patent applications in class Heavy metal containing DOAI

Patent applications in all subclasses Heavy metal containing DOAI